- published: 27 Jun 2014
- views: 6372
Sanofi S.A. is a multinational pharmaceutical company headquartered in Paris, France, as of 2014 the world's fifth-largest by prescription sales.[2] The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).[3] A key player i...
Diabetes and hypertension related series of health awareness shows aired on tvone global,directed and produced by Dr.syed ahsan Jamal. supported by sanofi aventis in the interest of public health
Nil Karaibrahimgil'in Sanofi Aventis şirketi için hazırladığı tanıtım şarkısı. http://www.twitter.com/niltakiptefan
French drugmaker Sanofi Aventis is breaking away from the strategy followed by most MNC pharma companies when it comes to rural marketing. After the launch of its rural market initiative Prayas, it is now looking at revamping its product launch strategy. The company feels a focused approach on fewer Hoechst prodcuts will help develop brands further.
Márcio Mussarela passa um dia em uma das maiores indústrias farmacêuticas do Brasil, para conferir de perto os benefícios que fazem dela uma das melhores para se trabalhar do país. Lá descobriu que os profissionais admiram e têm total liberdade de conversa com seus chefes. Além de acompanhar uma consulta que alguns colaboradores fizeram ao nutricionista e ao fisioterapeuta, ambos instalados na empresa. http://www.vocesa.com.br
"Единые Медицинские Системы" www.plavixsanofi.com.ua предлагают оригинальный препарат Плавикс произведенный исключительно во Франции на заводе Sanofi Clir SNC по самым выгодным ценам оптом и в розницу с аптечного склада в г. Киев. Наш ассортимент и цены : упаковка 84 таблетки - 1000 гривень (ок. 35 евро), упаковка 28 таблеток - 400 гривень (ок. 14 евро), блистер 28 таблеток без упаковки - 350 гривень ( ок. 12 евро) Препарат всегда в наличии и всегда в большом количестве. Срок годности не менее трех лет. Мы находимся по адресу: г. Киев, ул. Днепровская набережная, 33 ТЦ "Аркадия" тел. для справок +38 097 729 54 80 Заказать препарат можно в любую точку Украины через Новую Пошту или забрать лично из нашего склада. Следите за нами в соц. сетях: FB https://www.facebook.com/plavix75mg/ VC htt...
"Die Betriebsräte müssen darauf achten, dass die technisch mögliche Leistungs- und Verhaltenskontrolle nicht zu Ungunsten der Arbeitnehmer missbraucht wird", Marion Palme, Betriebsrätin bei der Sanofi-Aventis Deutschland GmbH
Robert Sebbag, VP access to medicines at Sanofi Aventis Group, talks about Biovision
Un clip pour rendre compte du chantier et de la réalisation une fois livrée du nouveau Centre de Recherche de Sanofi Aventis, inauguré en 2009 sur le site historique d'implantation du groupe pharmaceutique : la commune de Vitry-sur-Seine / Alfortville. Au delà simple film de suivi de chantier, ce film valorise le nouvel environnement de travail offert aux collaborateurs du groupe, tant en termes d'infrastructures que d"équipements propres à leurs métiers. Client : SANOFI AVENTIS http://www.groupe-cebtp.com/ Année de production : 2009 Thème, format : BTP, immobilier d'entreprise, pharmaceutique, médical, clip Une réalisation eoprod.com http://www.eoprod.com/portfolio-eoproduction.htm
Réalisation : SALAH ZIOUI
http://www.thecasesolutions.com/ This case is about The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights Get your The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights Case Solution at TheCaseSolutions.com TheCaseSolutions.com is the number 1 destination for getting the case studies analyzed. http://www.thecasesolutions.com/the-sanofi-aventis-acquisition-of-genzyme-contingent-value-rights-3-32389